Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer’s Meningococcal Vax Meets Phase III Endpoints | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Pfizer’s Meningococcal Vax Meets Phase III Endpoints

Demonstrates immune response against invasive meningococcal B strains

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer achieved positive results from two Phase III studies of TRUMENBA (Meningococcal Group B Vaccine). Both studies met all primary immunogenicity endpoints, demonstrating immune responses against certain invasive meningococcal B strains. One study included approximately 3,600 healthy individuals 10 through 18 years of age, and the other study included approximately 3,300 healthy individuals 18 through 25.  
 
“We are very pleased with these Phase III data that show immunogenicity and safety data consistent with findings that formed the basis for the accelerated FDA approval of TRUMENBA,” said Kathrin Jansen, Ph.D., senior vice president of Vaccine Research and Development for Pfizer Inc. “The Phase III data extend the body of evidence that supports vaccination of adolescents and young adults with TRUMENBA to help prevent serogroup B meningococcal disease.”
 
In October 2014, TRUMENBA was granted accelerated approval by the FDA for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics